Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 28 (BNIP3P28) is classified as a pseudogene, specifically a non-protein-coding segment of DNA that is homologous to the BNIP3 gene but typically carries inactivating mutations, preventing the production of a functional protein[2][4][11]. Pseudogenes may be transcribed into RNA and, in exceptional cases, their transcripts can have gene regulatory roles or be processed into non-coding RNAs, but no such functions have been demonstrated specifically for BNIP3P28[5][8][11]. The functional, protein-coding BNIP3 gene is known for roles in apoptosis and autophagy, but this does not apply to the pseudogene form BNIP3P28. As a result, BNIP3P28 is not a receptor, enzyme, or established therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 28 (BNIP3P28).